CDK4 and interstitial lung disease: A study that assessed the pulmonary toxicity of CDK4/6i by analyzing the publicly available FDA Adverse Event Reporting System demonstrated that interstitial lung disease represented 2.1% of total reports recorded for ABM but only 0.3% of total reports recorded for PAL and RIB36.